Note: Descriptions are shown in the official language in which they were submitted.
~3~
1 The present invention relates to a suppository,
containing as its principal ingredient, a one-to-one
complex vf sulfamethoxazole and trimethoprim (hereinafter,
to be referred to as SMX and TMP, respectively).
A pharmaceutical composition formed by mixing
SMX with TMP has been known as an antimicrobial agent
whlch performs an excellent synergetic action (See, for
instance, U.S.P. 3,341,541). It is still occupying an
important status in the field of treating the particular
infectious diseases caused by pathogenic bacteria
resistant to other synthetic bactericidal agents and
antibiotics. Though an old agent, it is still having an
irreplaceable importance in the field of chemotherapy.
However, such combination has a large dose as
described in the U.S.P. 3,341,541 (for instance, SMX
800 mg ~ TMP 160 mg, per day) to make the oral administra-
tion difficult as well as to cause any damages to stomach
or duodenum through which this combination agent is
absorbed. Therefore, the oral administration thereof
is not necessarily easy.
Attempts have hitherto been made to solve the
stated problem by administering the mixed preparation through
coelomata, for example, rectum, but a preparation confectioned
for the purpose by dispersing a simple mixture of SMX and
TMP in carrier has been found unsatisfactory because of its
inherent disadvantages which will be stated below.
1) During the manufacturing process:
In mixing and kneading operation of the active
ingredients with carrier, the viscosity of the composition
will rise abnormally to solidify, and this solidifying
- 1-
~13~ 6
l tendency will make the moldin~ into the required dosage
form very difficult.
2) After preparation:
Uncontrollable variances in physical properties,
for example, disintegration, dissolution and melting or
softening point are inevitable. These will make the
finished dosage form unpreferable in practical point
of view.
In addition to these, even with a Erefihly
molded preparation, blood levels of the each active
ingredients after predetermined period of administra-
tion cannot be attained as expected.
A proposal has been made to overcome these
disadvantages in, for instance, Germany lay-open print
2,415,660, wherein suppositories comprising two separate
layers each containing carrier and one of the active
ingredients, SMX or TMP. The separated layers may
optionally be isolated further with an insulating layer
composed prlmarily of carrier.
Although the proposed suppository might have
overcome at least partly the difficulties anciliary to
the manufacturing process, it is obviously inconvenient
in practlcal point of view because the manufacturing
process includes at least two and in some instances
three steps to obtain the finished product.
It is therefore the primary object of the
present invention to provide a suppository for chemo-
therapy containing a one-to-one complex of SMX/TMP,
which has overcome the stated disadvantages inheren-t
to the conventional preparations.
-- 2
113~ 6
1 Another ob~ect of the present invention is
to provide a process for preparing the suppositories
which may be in a form of homogeneous mass or rectal
capsule composed of a soft capsule filled with a
fluid or thixotropic material containing said complex.
Further objects and attendant advantages of
the present invention will be made clear to those skilled
in the art from the following description of the inven-
tion illustrated by way of examples.
According to the present invention, there is
provided a suppository comprising as its principal in-
gredient a one-to-one complex of sulfamethoxazole and
trimethoprim dispersed in a pharmaceutically acceptable
carrier.
This is based on a discovery of the present
inventors that these objects may be accomplished by
utilizing said complex, a molecular compound formed
by combining SMX with equimolecular amount of TMP,
disclosed in Japanese Patent No. 805,379 (Publication,
NO. 20,125/75) which primarily intends to improve the
objectionable taste of TMP.
Throughout this specification and claims, the
term suppository is used to include a unit dose having
a homogeneous solid form at room temperature which
melts rapidly in human coelomic ducts, as well as so-
called "rectal capsule" of a unit dose of soft capsule
filled with said dispersed substance. The soft capsule
is designed to disintegrate in human coelomic ducts to
release the ingredient contained therein in a time
dependent manner.
-- 3
~136~86
1 The suppository may optionally contain a
supplemental amount of sulfamethoxazole in addition to
the comp]ex. The amount may range from two to five
times as much as that of sulfamethoxazole component
in the complex.
The one-to-one complex is used to mean a
molecular compound formed by combining equimolecular
amount of sulfamethoxazole with trimethoprim, disclosed
in the previously described Japanese Patent.
The suppositories are primarily administered
through anus by inserting the same into the sufficient
depth of rectum but may otherwise be administered through
any other body coelomic ducts, for example, vagina as well.
In the other aspect of the present invention,
there is provided a process for preparing the stated
suppositories characterized in the use of one-to-one
complex of SMX/TMP in lieu of the simple mixture of
SMX and TMP.
In the formulating operation, one which is
obtained by dissolving an equimolecular mixture of
SMX and TMP in a solvent and then removing the solvent
by evaporation may likewise be used as the active in-
gredient in place of the isolated complex of SMX/T~IP
as is disclosed in the specification of the Japanese Patent.
The mixing ratio of the established mixture
preparation of SMX and TMP, co-trimoxazol (INN)
stipulated in Martindale: The Extra Pharmacopeia 27th
Ed. pp. 361-2, is fixed to be 5:1 to expect minimum
inhibition concentrations of the both ingredients of
12 ~g/ml and 0.6 ~g/ml in blood level in the case of
-- 4 --
~13~915 6
1 oral or intravenous administration.
Therefore, supplemental amount of SMX may
optionally be incorporated into the suppository.
This is imperative if the blood levels should accurately
correspond to the administered amounts with each of
the ingredient, and the complex should be equivalent
to the simple mixture of SMX and TMP.
It has however been found that the mixing
ratio should not necessarily be so obstenantly adhered
to, because the absorption of the respective ingredients
will depend on the species of the agent and subject to
be administered as well as the site of absorption.
The absorption of either ingredient through stomach or
intestine may differ from that through rectum as will
be apparent from the later description. No confirmation
has hitherto been made on the fixed or parallel relation-
ship among the absorption of SMX through stomach or
intestine, that through rectum, that of TMP through
stomach or intestine and that through rectum.
The dose of the suppositories will usually
range from 10 to 20 mg/kg of the complex together with
supplemental amount of SMX of about 0-50 mg/kg.
Normal period of administration may be from 12 to 18
hours.
The pharmaceutically acceptable carrier may
be any carrier or diluent which is conventionally used
in preparing suppositories or ointments and having no
substantial physiological hazards.
They may be exemplified as, oils of peanuts,
palm, olive, soy bean,sesamea, cottonseed, castor,
-- 5 --
113~ 6
1 linseed, rice bran, rapeseed and corn; fatty oils of
cacao butter, tallow and lauric fatty oil; any modified
substance of these obtained by hydrogenation, fatty acid
moiety substitution or acetylation as well as any esters
of saturated fatty acids with polyhydric alcohols.
Water soluble carriers may be exemplified as
polyethylene glycol, polypropylene glycol, glycerogelatine,
methyl cellulose and carboxymethyl cellulose.
Any surfactant having an only mild action to
biomembranes may equally be incorporated into the pre-
paration of the present invention in order to improve
or promote the absorption of the active ingredients
through the membrane. Of these surfactants, polyoxy-
ethylenesorbitan fatty acid esters, polyoxyethylene-
sorbitol fatty acid esters, polyoxyethylene fatty acids
esters, glycerine fatty acid esters as well as poly-
oxyethylene higher alcohol esters are exemplified as
non-ionic surfactants.
Esters of alkylsulfonic acid and esters of
polyoxyethylene alkyl sulfonate may be incorporated as
anionic surfactants. Polyoxyethylene alkylamine or
its amides are preparable cationic surfactant.
In addition to these, suitable emulsifier,
dispersing agent, viscosity adjusting agent, stabilizer,
and coloring agent may optionally be incorporated into
the suppositories in accordance with the requisite.
In the following paragraphs, the present
invention will be illustrated in further detail by
referring to the preferred embodiments-
- 6 -
~3fi~6
1 Example 1. (Suppository)
1. Manufacturing process:
The carrier, Wi-tepsol (Registered Trade Mark
of Dynamit Nobel A.G.r West Germany: a mixture of mono-,
di- and tri- glycerides of C12-C18 saturated fatty acid)
was rnelted at 50C and added thereto active ingredients
in accordance with the mixing ratios in Table I below,
respectively while being stirred to be uniformly and
evenly dispersed in the carrier. The dispersi.on was
subdivided and cooled -to be molded into homogeneous
solid masses, each havin~ 1 g weight to obtain the
intended dosage forms.
Table I
Formula A B C D
(Active (Carrier) (Invention) (Control)
ingredients)
SMX/TMP complex 15 15
SMX 33 7 40
TMP 8 8
Witepsol 85 52 85 52
(Total) 100 100 100100
(In each of the formulae, the molar ratio of TMP is
kept constant while those of others are varied)
2. Measurements of melting points:
The results of the measurement conducted in
compliance with the second method stipulated in Japan
- 7 -
1~3~;9~
1 Pharmacopeia 9th Ed., with the freshlv molded dosage
forms and the ones aged at 30C for one month are
summarized in Table II.
TABLE II (C, average of 6 pieces)
Formula A B C D
(Freshly molded)36.0 36.3 36.8 37.5
(A~ed at 30C for 1 36.5 36.8 37.5 38.8
month)
3. Dissolution:
The measurements of the dissolution rate were
performed in compliance with the paddle method stipulated
in U.S. Pharmacopeia 4th Ed., Supplements, with the fresh
and aged ones. Ingredients dissolved into a distilled
water (900 ml), 60 minutes after the immersion at 37C
and 100 r.p.m. were determined to be summarized in the
following Table III.
TABLE III (Q ~ average of 6 ~ieces)
_.._
Formula r------- B ~ D
Ingredient
determined
(Freshly SMX 72.1 65.0 55.9 40.5
molded) TMP 72.5 60.0 51.2 25.9
(Aged at 30C SMX 65.3 58.3 30.7 20.3
for 1 month)
TMP 67.2 55.5 32.3 18.8
-- 8 --
1 (~uantitative determination of SMX were performed by High
Performance Li~uid Chromatography, while those of TMP were
performed by Gas Chromatography).
4. Plasma levels after rectal administration in dogs:
The freshly molded suppositories (each 1 g) of
Formula A, B, C and D were used in this stud~ for evaluat-
ing the rectal absorption of the active ingredients.
Each five male beagles (average weight, 10 kg)
had been fasted for 17 hours and evacuated before being
inserted with the suppositories into their recta at 4 cm
depth from anus.
Blood samples were taken from paw vasculars
at each sampling time and centrifuged to obtain the
plasma for the evaluation. The quantitative determina~
tions of the active ingredients were made in accordance
with the method as previousl~ described to obtain the
result summarized in Table IV.
TABLE IV
Plasma levels (~lg/ml) after administration
A SMX4.0 6.8 31.4 43.9 40.9 41.2 33.8 18.4 5.9
T~P0.50 1.10 1.20 0.98 1.00 1.05 0.90 0.60 0.25
B SMX18.1 15.1 67.4 73.6 75.0 77.9 70.1 58.2 20.1
TMP0.33 0.75 0.84 0.91 1.15 .20 1.05 0.82 0.35
~ _ . .. . _
C SMX1.2 3.9 11.9 24.9 30.2 28.7 25.5 15.7 1.3
TMP0.33 0.78 0.75 0.81 0.75 0.69 0.55 0 46 0.16
SMX3.0 14.3 35.0 48.1 45.2 44.9 44.8 39.3 7.1
D TMP0.18 0.33 0.39 0.52 0.48 0.54 0.48 0.48 0.12
. _ ` _ _ ~ ._ _
g
1~3~i9~
1 In performing the experiments whose results are
briefly presented, the following facts are confirmed to
support the unpredictable advantages of the present
invention over the prior art, together with the results
themselves.
]) Moldability:
In the manufacturing process of the products
in accordance with the formulae A and B, a conventional
manner customary to the preparation of suppositories was
able to be applied without any difficulty and without
requiring any substantial modification, by virtue of
the suitable fluidity maintained throughout the kneading
operation.
With the products of the formulae C and D,
however, the viscosities of the mixture had rised
abnormally during the dispersing and kneading operations
to result in a premature solidification. This abnormal
tendency in the rising viscosity and solidification made
the casting of the dispersion into molds very difficult
and in some instances almost impossible.
2) Melting Point:
With the freshly molded products, bo-th sets of
suppositories melted around body temperature. With the
aged products, however, the suppositories of the formulae
C and D, showed remarkable rises in melting point as
compared with those of the formulae A and s. Rise in
melting point means the corresponding prolongation in
melting time in coelome to make the product unacceptable.
In general, a rise in melting point of a suppository by
one degree centigrade around the body temperature mav
-- 10 --
~13~ 6
1 well taken as serious as a fatal disadvantage which
would make the practical application of the product
impossible.
3) Dissolution:
A11 of the products of the formulae C and D
were found to be inferior to those of A and B in their
dissolution properties, even in the freshly molded ones
not to mention the aged ones.
It was found that the aged products o~ the
formulae C and D were so seriously deteriorated that
they were unable to be put into practical services.
4) Absorption through rectum:
The products of formula A brought about concent-
rations in blood levels of the respective ingredients
about 1.5 - 2 times as high as that brought about by
that of the formula C in the same effective dose.
The similar results was observed in a comparison of the
product of the formula B with that of D.
Obviously, this property is closely associated
with the melting point and dissolution, it is recognized
that there is no need to further confirm the difference
between the aged products of the formulae C and D and
those of A and B.
From the stated facts and analysis, it is
safely concluded that a satisfactory bactericidal action
can be expected by administering the preparation of the
complex in a dose of about 15 mg/kg, in an administering
period of from 12 to 18 hours.
Example 2. (Rectal Capsule)
1) Manufacturing process:
-- 11 --
~3~ 6
1 In accordance with the compounding ratios in
Table V below, polyoxyethylene oleyl ether is dispersed
into sesamea oil at 40C. To this dispersion the active
ingredients were added under stirring to obtain a uniform
suspension. This was subdivided into each one gram to
be encapsulated in a soft gelatine capsule.
TABLE V
~ = orumla (g)¦ E ¦
(Active ingredients) (Carrier) (Invention) (Control)
SMX/TMP complex 30
SMX 66 80
TMP 16
Sesamea oil 94 94
Polyoxyethylene 10 10
oleyl ether
Total 200 200
In the dispersing and kneading operation, fluidity
of the suspension in sesamea oil in the formula F was lost
to show a solidifying tendency to make the filling opera-
tion difficult. In that of the formula E, the fluidity
was maintained satisfactorily throughout the operation
to ensure an easy encapsulation.
2) Disintegration:
Experiments were performed on the soft capsules
obtained above, in accordance with the test method for
capsule disintegration stipulated in Japan Pharmacopeia
- 12 -
1~36~36
1 9th Ed, wherein distilled water was employed as the test
liquid in place of the artificial gastric juice, to obtain
the disintegrations (expressed in terms of time required
for the disintegration in minutes) described in Table VI.
TABLE VI
. __
Formula Freshly molded Aged at 30C for one month
_ _ __ ..
E 10- 15 15 -20
F 60 - 70over 120
The product of the formula E suffered no
substantial aging effect and showed a satisfactory dis-
integration. That of the formula F was subjected to
considerable deterioration in the manufacturing process
to show an abnormally prolonged disintegration time even
after freshly molded, and it was found that the practical
service of this product is substantially impossible because
it did not disintegrate for as long as 120 minutes.
- 13 -
